Abstract: There is growing evidence that chemerin, a novel adipokine elevated in obesity and metabolic syndromes, plays a crucial role in advanced atherosclerosis. This study aimed to determine the chemerin levels in diabetes and evaluate the effects of increased chemerin on early atherosclerosis.
INTRODUCTION
T ype 2 diabetes mellitus (T2D) is associated with accelerated atherosclerosis and increased incidence of cardiovascular morbidity and mortality. Despite our growing understanding on the pathophysiology of coronary heart disease (CHD) in subjects with T2D, a large number of diabetic subjects still experience cardiovascular disease (CVD).
1,2 Therefore, early detection of asymptomatic atherosclerosis in diabetes is a promising strategy to reduce the risk of diabetic macrovascular complications and improve the prognosis as well. Many studies have shown that changes in vascular structure, such as carotid intimal thickening, 3 arterial compliance and stiffness, 4 and endothelial dysfunction, 1, 5, 6 occur in the early course of T2D and lead to accelerated atherosclerosis. 7, 8 In addition, several vascular adhesion molecules such as intercellular adhesion molecule-1 (ICAM-1), vascular adhesion molecule-1 (VCAM-1), E-selectin, and P-selectin, which are well established vascular inflammatory markers and predictors of atherosclerosis, are also elevated during the early stage of T2D. 9, 10 However, the underlying mechanisms linking T2D with these vascular abnormalities remain poorly understood.
Adipose tissue, previously regarded as a passive depot for lipid storage and release of energy-rich substrates, is now considered a major active endocrine organ. Adipocytes respond to metabolic and inflammatory stimuli by secreting a variety of molecules known as adipokines. They serve as effectors to modulate atherosclerosis and are candidate risk factors for CVD. 11 Chemerin, first described in 2007, was found to be highly expressed in adipose tissue, 12 liver, and cells of the innate immune system as well, where it modulates the function of innate immune cells and may further link obesity and inflammation. 13 Like many other adipokines, chemerin is dysregulated in obesity. In human, the serum level of chemerin is associated with several key factors of metabolic syndromes. Retrospective and cross-sectional studies suggested that T2D patients had significantly higher chemerin levels than normal subjects. 14, 15 Notably, the pathogenic role of chemerin in CAD has been increasingly recognized. Yan et al 16 have demonstrated that elevating serum chemerin levels have been observed in patients with CAD, as well, in association with the severity of coronary atherosclerosis. Lehrke et al 17 reported systemic chemerin levels was related to coronary plaque burden in Caucasian subjects, although the association was lost after adjusting for established risk factors of CAD. 17 Furthermore, a study examining the differential expression of multiple adipokines in human periaortic and pericoronary adipose tissue reported that chemerin expression in both of these adipose depots was highly correlated with atherosclerosis in their respective vessels. 18 Chemerin is expressed in inflamed tissues and is involved in chemotactic recruitment of macrophages and other antigen presenting cells. These findings suggest a role of this adipokine in inflammatory status and atherosclerosis. 19 Although the association of chemerin with established atherosclerosis has been investigated, limited data are available regarding the relationship between chemerin and early atherosclerosis. To our knowledge, only Yoo et al 20 reported that in obesity, serum chemerin level was an independent predictive variable for increased brachial-ankle PWV (baPWV), even after adjusted for other cardiovascular risk factors. However, the correlation of chemerin with subclinical atherosclerosis in subjects with T2D has not been investigated.
The present study was designed to determine the importance of chemerin as a novel marker for endothelial activation and subclinical atherosclerosis in T2D, by comparing it with other markers of metabolic syndrome.
SUBJECTS AND METHODS

Study Design and Subjects Enrolled in the Study
The study used was approved by the Committees on Ethics of Nanjing General Hospital of Nanjing Command, and all subjects gave informed consent in this study.
A NGT group) participated in the study. The baseline characteristics of the patients were shown in Table 1 . Diabetes was diagnosed according to current WHO criteria. All patient conditions were newly diagnosed, and they were not treated with oral hypoglycemic agents or diet control. Subjects were excluded if they met any of the following criteria: type 1 diabetes; a history of ketoacidosis; macrovascular (CVD, congestive heart failure, myocardial infarction, stroke, or 
Physical Examination and Laboratory Tests
A physical examination was performed in all study participants. Height (m) and weight (kg) were measured to calculate body mass index (BMI) as weight/height squared (kg/m 2 ). Blood pressure was measured twice using a cuff sphygmomanometer after sitting at least 15 minutes. Waist circumference, an index of visceral fatness, was performed at the midpoint between the lower rib margin and the iliac crest.
After overnight fasting, blood samples were collected between 8:00 and 10:00 am in the morning, and plasma was obtained by centrifugation at 4 8C for 30 minutes. Glucose was measured shortly after blood collection and samples for other assays were stored at À70 8C. The plasma levels of glucose, lipid profiles, high sensitivity C-reactive protein (hs-CRP), insulin, and adipokines including chemerin, leptin, and adiponectin were determined as previously described. 21 The interand intraassay variability of adiponectin and chemerin were 6.4% and 5.1%, 8.1% and 7.2%, respectively. Endothelial activation molecule concentrations were measured including soluble E-selectin, P-selectin, VCAM-1, and ICAM-1 using ELISA assay (Millipore, MC) and inter-and intraassay variability were 6.0 and 5.4, 6.5 and 4.8, 7.7 and 4.1, 5.2 and 3.1, respectively. Homeostasis model assessment of insulin resistance (HOMA-IR) was calculated as the product of the insulin reading (mIU/L) and the plasma glucose value (mmol/L) divided by 22.5. 
Flow-Mediated Dilation (FMD) and IntimaMedia Thickness (IMT) Measurement
Detailed protocols for subclinical atherosclerosis assessment have been previously described: 21 Endothelial function assessed as FMD of the brachial artery by an ultrasound machine (HP Sonos5500, United States of America ), and carotid atherosclerosis measured as carotid IMT using a high-resolution ultrasound scanner (Acuson Sequoia 512; Siemens Medical Solutions, USA).
Statistical Analysis
Statistical analyses were performed using SPSS version 13.0 (Chicago, IL). Continuous variables are expressed as means AE standard deviation or median (interquartile range). The log values of variables that failed the normality test were calculated before analysis. Comparisons between the groups were assessed by ANOVA, and the correlation analysis was performed by calculating the Pearson correlation coefficient. Multivariate linear regression and logistic regression modeling were performed to evaluate association between variables. A P-value < 0.05 was considered to represent statistically significant.
RESULTS
Baseline Characteristics, Metabolic Risk Factors, Adipokines, Adhesive Molecules, and Early Atherosclerosis Parameters in Diabetic and NGT Control Groups
Basic characteristics of the patients were shown in Table 1 . Age and gender distribution were comparable between both groups. Compared with NGT subjects, BMI, waist circumference, diastolic blood pressure (DBP), fasting glucose, Oral glucose tolerance test (OGTT) 2-hour glucose, plasma insulin, HOMA-IR, total cholesterol, triglyceride, LDL-C, and plasma hs-CRP levels were higher in diabetic patients (P < 0.01 in all comparisons). No significant difference was observed in systolic blood pressure and HDL-C levels between the 2 groups.
As expected, compared with NGT control subjects, the plasma chemerin and leptin levels were significantly higher whereas adiponectin levels were lower in diabetic patients (P < 0.01). There were also striking differences in plasma ICAM-1 and E-selectin in diabetic patients (P < 0.01), but VCAM-1 and P-selectin were not different. In addition, diabetic patients had lower FMD and thicker carotid IMT (P < 0.01).
For the whole study population, those with elevated chemerin levels were more likely to have T2D. Following adjustment for age, gender, and metabolic risk factors, chemerin was independently associated with T2D (odds ratio [OR] ¼ 1.352, 95% CI: 1.181-1.543, P < 0.01).
Chemerin in Type 2 Diabetic Subjects
The correlations of the plasma chemerin concentration with metabolic risk factors in T2D group were shown in Table 2 . After adjustment for age and sex, chemerin level was significantly positively associated with BMI, DBP, fasting glucose, fasting insulin, OGTT2-hour glucose, triglyceride, total cholesterol, LDL-cholesterol, hs-CRP, and letpin, and negatively associated with adiponectin, but not with systolic blood pressure, waist circumference, and HDL-cholesterol in diabetic patients. Figure 1B and D) , but there was a strong positive association with ICAM-1 and E-selectin (see Figure 1A and C). We also explored that plasma chemerin level was negatively associated with brachial FMD and positively with carotid IMT (see Figure 2A and B). Although the abovementioned variables were strongly intercorrelated, the unadjusted associations of chemerin with adhesive molecules and earlier atherogenesis may be confounded. Therefore
Multiple Regression Analysis for Predictors of Elevated Adhesive Molecules in Diabetic Patients
Multivariate regression analysis was performed to detect factors independently related to endothelial activation measured by ICAM-1, VCAM-1, P-selectin, and E-selectin. As given in Table 3 , univariate analysis demonstrated age and sex-adjusted ICAM-1 was positively associated with BMI, waist circumference, fasting glucose, OGTT2-hour glucose, fast insulin, HOMA-IR, triglyceride, total cholesterol, LDL-cholesterol, hs-CRP, E-selectin, leptin, chemerin and negatively related to adiponectin in diabetic patients. The relationship of ICAM-1 with chemerin still persisted even after adjustment for age, sex, glucose homeostasis, lipid profiles, hs-CRP, and adipokines (b ¼ 0.192, P ¼ 0.017). Age and sex adjusted Eselectin was also significantly correlated to DBP, total cholesterol, hs-CRP, adiponectin, leptin, and chemerin, but the association between E-selectin and chemerin was lost in multivariate analysis. However, no correlation of plasma VCMA-1 and Pselectin concentrations with aforementioned variables was detected in our study (Table 4) .
Logistic Regression Analysis for Predictors of Subclinical Atherosclerosis in Type 2 Diabetic Patients
The association between progression to atherosclerosis and chemerin levels was assessed using logistic regression analysis. Dichotomous outcome variables (men: FMD 6.3% and IMT > -0.96 mm; women: FMD 7.1% and IMT > -0.85 mm) were employed to assess whether chemerin impaired vasodilation and enhanced thickening of carotid vessel wall. The result of logistic regression analysis was shown in Table 5 . Increasing concentrations of chemerin was associated with 1.13-fold increased risks of having endothelial dysfunction (OR ¼ 1.131, 95% CI: 1.095-1.167, P < 0.01) and 1.17-fold increased risks of enhanced carotid vessel thickness (OR ¼ 1.171, 95% CI: 1.114-1.231, P < 0.01) after adjusted for age and sex. These relations remained significant even after adjustment for metabolic variables (BMI, glucose homeostasis, and lipid profiles), adipokines, and adhesive molecules. 
DISCUSSION
We present the first study to examine the relationship of circulating chemerin with endothelial cell activation, as well as with earlier atherosclerosis in patients with new diagnosed T2D. We found that plasma chemerin levels were associated with markers of endothelial activation including ICAM-1 and Eselectin in diabetic patients. Furthermore, the chemerin levels were significantly associated with early changes (both structural and functional) of the vasculature in diabetic patients. These findings indicate that diabetic patients with elevated chemerin levels are at an increased risk for cardiovascular complications, and chemerin plays an important role in atherogenesis from very early stages in diabetic patients.
Chemerin is an adipocyte-derived protein, which not only influences adipocyte differentiation and metabolism, but also has a role in adaptive and innate immunity. Therefore, chemerin may be a candidate protein in obesity-related disorders. 23, 24 In the current study, the plasma chemerin levels were found to be significantly increased in the diabetic group compared with NGT group, and it was also correlated positively with fasting glucose, fasting plasma insulin, OGTT2-hour glucose, HOMA-IR, total cholesterol, triglyceride, LDL-C, and plasma CRP Ã Natural logarithmic transformation was used in analysis. levels in diabetic subjects. Furthermore, logistic regression analysis demonstrated that chemerin was independently associated with diabetes even after adjusted for age, sex, and metabolic risk factors. In line with our studies, Yang et al 25 and ElMesallamy et al 15 had reported that circulating chemerin levels were elevated in type 2 diabetes and had been shown to correlate with insulin resistance independently of BMI and fasting insulin. Lee and coworkers 26 showed that decrease in serum chemerin levels was associated with improved insulin sensitivity in overweight and obese T2D patients. Recently, Bobbert et al 27 had published prospective data investigating the association between chemerin and the risk of T2D. 27 A total of 440 subjects with normal glucose tolerance were enrolled in the study and mean follow-up of participants was 5.3 years. Their results showed that chemerin predicted the onset of T2D and prospective changes in fasting glucose and HbA1c were associated with chemerin. However, other studies by Bozaoglu et al 12 and Takahashiet al 28 did not find differences of chemerin levels between patients with T2D and controls. This difference between present studies might be related to the age of the patients, the adipose mass content, duration of diabetes, complications, and/or to race of the subjects. The mechanisms by which chemerin impacts glucose homoeostasis are still unclear, and experiment studies and large prospective investigation are required to clarify the relation between chemerin and diabetes incidence and eventually also the therapeutic potential of chemerin.
The diabetic state is hallmarked by abnormalities in a cluster of strongly interrelated clinical and metabolic factors that are likely to contribute to increased atherosclerosis susceptibility. Several studies suggested chemerin levels as predictor of advanced atherosclerotic lesions. 16 However, the involvement of chemerin in very early stages of atherosclerosis was not examined so far. Furthermore, from a pathophysiological and potentially therapeutic point of view, it seems relevant to assess the role of chemerin on the early stage of atherosclerotic disease in a population-based sample.
Endothelial recruitment and monocytes adhesion are the earliest detectable events in the pathogenesis of atherosclerosis. 29 The initial steps of endothelium/leukocyte interactions are considered to involve selectins (E-, P-, and L-selectin), and ICAM-1 and VCAM-1 are crucial for adhesion and migration of leukocytes into the subendothelium. 30 So, the elevation of cell adhesive molecules is related to the higher morbidity, 31 and these cytokines are considered as reliable biomarkers of endothelial activation and inflammation in diabetic group. 32 We provided evidence that the plasma chemerin levels were strongly and independently correlated with measures of endothelial activation including ICAM-1 and E-selectin in diabetic patients, independent of metabolic parameters, and other adiopkines. Similar to our study, Landgraf et al 33 reported that chemerin was the strongest predictor of ICAM-1 and E-selectin independent of BMI in obese children. Furthermore, on the cellular level, chemerin directly induced ICAM-1 and E-selectin expression in endothelial cells in vitro. Although some studies had shown the involvement of VCAM-1 and P-selectin in the development of atherosclerosis, we did not detect the association between circulating chemerin levels with soluble VCAM-1 and P-selectin, and these 2 molecules serum levels showed no significant differences between diabetic and NGT groups. ICAM-1 and E-selectin, not VCAM-1, have been shown to be independent early markers of atherosclerosis and incident coronary heart disease 34 and appear to predict macrovascular disease within the diabetic population. 35 Impaired FMD and enhanced carotid IMT are also established markers for early atherosclerosis 36 and there are observations showing that carotid IMT and FMD can predict future cardiovascular events in diabetic patients. 37 Toward this, we measured FMD and carotid IMT and our results showed that chemerin level was an independent predictor of impaired endothelial function and early structural changes of arteries in diabetic patients. To the best of our knowledge, this is the first study that earliest stages of atherosclerosis as assessed by decreased FMD and increased IMT are associated with hyper-chemerinemia in diabetic patients. However, the relationship between chemerin and early atherosclerosisis is controversial. A study in obese subjects by Yoo et al 20 demonstrated chemerin was revealed not to be associated with carotid IMT. Therefore, further clinical data are required to establish the effect of chemerin on early atherogenesis in different population.
Accumulating evidence from preclinical and animal studies suggests chemerin has a causal role in vasculature and induces the early inflammatory reactions and recruitment of inflammatory cells to endothelium. In vitro, chemerin impaired endothelial dependent vascular relaxation by reducing NO production and decreasing NO-dependent cGMP signaling. 38 Chemerin has also been shown to activate adhesion molecules and induce endothelial cells inflammation directly. 33, 39 Moreover, chemerin promotes the adhesion of macrophages to fibronectin and VCAM-1 by promoting clustering of the integrins which plays a central role of vascular remodeling. 40 In addition, alteration in insulin sensitivity and glucose uptake by chemerin in adipocytes and skeletal muscle could contribute to development of atherosclerosis. 41 Nevertheless, the exact pathophysiologic implication of chemerin in early atherosclerosis also remains to be clarified by further comprehensive investigations.
The present study has several potential limitations. First, our study population was relatively small and various nonsignificant associations would become statistically significant if larger sample sizes were adopted. Second, our data suggested that chemerin was involved in the pathophysiology of earlier atherosclerosis in T2D. But the observation data cannot prove any causal relationship, which need to be supported by further experiment studies. Third, our study was performed in newly diagnosed diabetic patients from outpatient center. These patients were younger and it is not representative for the general population.
In conclusion, our data demonstrate that in newly diagnosed T2D patients, plasma chemerin levels were independently associated with markers of endothelial activation including ICAM-1 and E-selectin. Moreover, the existence of impaired vascular function (FMD) and structure (IMT) with high serum chemerin concentrations was detectable in newly diagnosed T2D patients. These dynamic relationships between chemerin and atherosclerosis may give a meaningful contribution to the understanding of pathogenesis of atherosclerosis in diabetic patients. However, clinical evidence needed to be confirmed in large-scale prospective investigation, and animal studies are required to elucidate the role of chemerin in atherosclerosis and CVDs.
